Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Sensei Biotherapeutics Inc SNSE

Healthcare Biotechnology
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company’s Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also... see more

Current News (NDAQ:SNSE)

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

GlobeNewswire November 14, 2025

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

GlobeNewswire October 30, 2025

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

GlobeNewswire October 17, 2025

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

GlobeNewswire September 23, 2025

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire September 3, 2025

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire August 5, 2025

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

GlobeNewswire July 30, 2025

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

GlobeNewswire June 13, 2025

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

GlobeNewswire May 6, 2025
View More News ››

Opinion & Analysis (NDAQ:SNSE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SNSE)

Buy buddy buy because it's taking off this morning.

Otherwise FOMO for you fellas out there today anyway,so good luck to all of you guys
coolfooldumbguy - December 5, 2025

Sensei Biotherapeutics (SNSE): A Clinical-Stage Immuno-Oncol

Interesting play in the immuno-oncology space. SNS-101 looks promising with early clinical data showing no dose-limiting toxicities and...
MikeTester - January 23, 2025

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE): Advancing Novel

http://beyondspx.com/2024/08/02/sensei-biotherapeutics-inc-nasdaqsnse-advancing-novel-immuno-oncology-therapies-with-promising-pipeline/
MikeTester - August 3, 2024

SNSE has given my portfolio such a beating.

Nothing positive out of this one. True bummer.
stockDAD1 - January 28, 2022

SNSE has given my portfolio such a beating.

Nothing positive out of this one. True bummer.
stockDAD1 - January 28, 2022
View more Bullboard ››

Grizzly Discoveries Inc

Grizzly Discoveries Inc

Grizzly Discoveries Inc. engages in the acquisition, exploration, and development of precious and base metals properties ...
View More »

Podcasts